Cargando…
Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review
The WHO recommends integration of universal mass vaccination (UMV) against hepatitis A virus (HAV) in national immunization schedules for children aged ≥1 year, if justified on the basis of acute HAV incidence, declining endemicity from high to intermediate and cost-effectiveness. This recommendatio...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360128/ https://www.ncbi.nlm.nih.gov/pubmed/27786671 http://dx.doi.org/10.1080/21645515.2016.1242539 |
_version_ | 1782516538117455872 |
---|---|
author | Stuurman, Anke L. Marano, Cinzia Bunge, Eveline M. De Moerlooze, Laurence Shouval, Daniel |
author_facet | Stuurman, Anke L. Marano, Cinzia Bunge, Eveline M. De Moerlooze, Laurence Shouval, Daniel |
author_sort | Stuurman, Anke L. |
collection | PubMed |
description | The WHO recommends integration of universal mass vaccination (UMV) against hepatitis A virus (HAV) in national immunization schedules for children aged ≥1 year, if justified on the basis of acute HAV incidence, declining endemicity from high to intermediate and cost-effectiveness. This recommendation has been implemented in several countries. Our aim was to assess the impact of UMV using monovalent inactivated hepatitis A vaccines on incidence and persistence of anti-HAV (IgG) antibodies in pediatric populations. We conducted a systematic review of literature published between 2000 and 2015 in PubMed, Cochrane Library, LILACS, IBECS identifying a total of 27 studies (Argentina, Belgium, China, Greece, Israel, Panama, the United States and Uruguay). All except one study showed a marked decline in the incidence of hepatitis A post introduction of UMV. The incidence in non-vaccinated age groups decreased as well, suggesting herd immunity but also rising susceptibility. Long-term anti-HAV antibody persistence was documented up to 17 y after a 2-dose primary vaccination. In conclusion, introduction of UMV in countries with intermediate endemicity for HAV infection led to a considerable decrease in the incidence of hepatitis A in vaccinated and in non-vaccinated age groups alike. |
format | Online Article Text |
id | pubmed-5360128 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-53601282017-03-29 Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review Stuurman, Anke L. Marano, Cinzia Bunge, Eveline M. De Moerlooze, Laurence Shouval, Daniel Hum Vaccin Immunother Review The WHO recommends integration of universal mass vaccination (UMV) against hepatitis A virus (HAV) in national immunization schedules for children aged ≥1 year, if justified on the basis of acute HAV incidence, declining endemicity from high to intermediate and cost-effectiveness. This recommendation has been implemented in several countries. Our aim was to assess the impact of UMV using monovalent inactivated hepatitis A vaccines on incidence and persistence of anti-HAV (IgG) antibodies in pediatric populations. We conducted a systematic review of literature published between 2000 and 2015 in PubMed, Cochrane Library, LILACS, IBECS identifying a total of 27 studies (Argentina, Belgium, China, Greece, Israel, Panama, the United States and Uruguay). All except one study showed a marked decline in the incidence of hepatitis A post introduction of UMV. The incidence in non-vaccinated age groups decreased as well, suggesting herd immunity but also rising susceptibility. Long-term anti-HAV antibody persistence was documented up to 17 y after a 2-dose primary vaccination. In conclusion, introduction of UMV in countries with intermediate endemicity for HAV infection led to a considerable decrease in the incidence of hepatitis A in vaccinated and in non-vaccinated age groups alike. Taylor & Francis 2016-10-27 /pmc/articles/PMC5360128/ /pubmed/27786671 http://dx.doi.org/10.1080/21645515.2016.1242539 Text en © The Author(s). Published with license by Taylor & Francis http://creativecommons.org/licenses/by/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted. |
spellingShingle | Review Stuurman, Anke L. Marano, Cinzia Bunge, Eveline M. De Moerlooze, Laurence Shouval, Daniel Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review |
title | Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review |
title_full | Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review |
title_fullStr | Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review |
title_full_unstemmed | Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review |
title_short | Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review |
title_sort | impact of universal mass vaccination with monovalent inactivated hepatitis a vaccines – a systematic review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360128/ https://www.ncbi.nlm.nih.gov/pubmed/27786671 http://dx.doi.org/10.1080/21645515.2016.1242539 |
work_keys_str_mv | AT stuurmanankel impactofuniversalmassvaccinationwithmonovalentinactivatedhepatitisavaccinesasystematicreview AT maranocinzia impactofuniversalmassvaccinationwithmonovalentinactivatedhepatitisavaccinesasystematicreview AT bungeevelinem impactofuniversalmassvaccinationwithmonovalentinactivatedhepatitisavaccinesasystematicreview AT demoerloozelaurence impactofuniversalmassvaccinationwithmonovalentinactivatedhepatitisavaccinesasystematicreview AT shouvaldaniel impactofuniversalmassvaccinationwithmonovalentinactivatedhepatitisavaccinesasystematicreview |